861 results on '"Xiao, Lianchun"'
Search Results
152. Failure Patterns in Patients With Esophageal Cancer Treated With Definitive Chemoradiation†
153. Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: Results of a randomized clinical trial
154. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy
155. V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials
156. CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia
157. Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study
158. Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
159. The role of ALBI and IGF-CTP score in refining prognostication of HCC.
160. Treatment outcome and prognostic indicators in 26 cases of fibrolamellar hepatocellular carcinoma under interferon based therapy.
161. MP72-05 CORRELATION BETWEEN BMI AND OUTCOMES IN PATIENTS TREATED WITH BCG IMMUNOTHERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER
162. A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer
163. A randomized study evaluating tailoring of advanced/metastatic colorectal cancer (mCRC) therapy using circulating cell-free tumor DNA (ctDNA) (TACT-D).
164. Impact of antibiotic exposure on the efficacy of immune checkpoint blockade in MSI-H metastatic CRC.
165. Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer
166. IGF-1 Child-Turcotte-Pugh score as a predictor of overall survival to therapy in CTP-A, BCLC stage C patients with advanced hepatocellular carcinoma.
167. Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers
168. Nivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer
169. Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients
170. Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia
171. Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography
172. Supports and Barriers to Home-Based Physical Activity During Preoperative Treatment of Pancreatic Cancer: A Mixed-Methods Study
173. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma
174. Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation
175. Multimodal kidney‐preserving approach in localised and locally advanced high‐risk upper tract urothelial carcinoma.
176. Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray
177. Gene expression profiling of diffuse large B-cell lymphoma supervised by CD21 expression
178. Overexpression of Cxcr4 Predicts Adverse Overall and Event-Free Survival in Patients With Unmutated Flt3 Acute Myeloid Leukemia With Normal Karyotype
179. Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer
180. Activity of the dietary antioxidant ergothioneine in a virus gene-based assay for inhibitors of HIV transcription
181. MGMT Promoter Methylation and Field Defect in Sporadic Colorectal Cancer
182. Association between ductal fluid proteomic expression profiles and the presence of lymph node metastases in women with breast cancer
183. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study
184. Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma
185. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial
186. Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols
187. Sarcomatoid carcinoma presenting as cancers of unknown primary: a clinicopathological portrait
188. Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA
189. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial
190. Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis
191. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
192. IGF-Child-Pugh score as a predictor of treatment outcome in advanced hepatocellular carcinoma patients treated with sorafenib.
193. Molecular profiling by circulating tumor DNA (ctDNA) and benefit from anti-PD-1 in HCC.
194. Clinical and prognostic significance of serum levels of fatty acid binding proteins in hepatocellular carcinoma (HCC).
195. Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases
196. Outcomes of patients with metastatic clear cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
197. IGF-Child-Pugh score as a predictor of treatment outcome in Child-Pugh A, advanced hepatocellular carcinoma patients undergoing sorafenib therapy.
198. FOLFIRI in advanced biliary tract cancers.
199. Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma
200. Home-Based Exercise Prehabilitation During Preoperative Treatment for Pancreatic Cancer Is Associated With Improvement in Physical Function and Quality of Life
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.